A regional health body, ministry of health, or international donor has invested in a regulatory harmonisation initiative, institutional capacity programme, or local pharmaceutical sector development. They require an objective, independent evaluation of what the investment achieved, backed by credible recommendations that hold authority in front of member states.
Evaluation of national medicines regulatory authorities and public Quality Control laboratories.
Mid-term and end-of-project appraisals evaluated against formal results and sustainability frameworks.
Comprehensive studies mapping pharmaceutical manufacturing capacity, production constraints, and market supply.
Development of multi-year strategic plans and regional harmonisation roadmaps.
Regional stakeholder research and consensus-building across member states in English and French.
Facilitating regional workshops to present findings and secure inter-governmental alignment.
Capacity building for regulatory personnel in QMS, GMP inspectorate methods, and dossier evaluation delivered concurrently with assessment assignments.
Independent end-of-project appraisal of the US$3m West African Medicines Regulatory Harmonisation project across 15 ECOWAS countries, delivered remotely during the COVID-19 pandemic.
Region-wide study mapping, quantifying, and reviewing local medicines manufacturing across all 15 ECOWAS member states.
Expert authorship contributions to the ECOWAS Regional Pharmaceutical Plan published by WAHO in 2014.
Led by Dr Chinedu Madichie alongside Mr Benjamin Botwe (World Bank consultant on ECOWAS harmonisation since 2012; adviser to WHO, AU, and USP; co-author of the African Medicines Agency legal framework). Supported by senior specialists in pharmaceutical industry policy and French-speaking assessors resident across West Africa.
